Clinical spectrum of high-titre GAD65 antibodies.
Adrian BudhramElia SechiEoin Patrick FlanaganDivyanshu DubeyAnastasia ZekeridouShailee S ShahAvi GadothElie NaddafAndrew McKeonSean J PittockNicholas L ZalewskiPublished in: Journal of neurology, neurosurgery, and psychiatry (2021)
High-titre GAD65 antibodies were suggestive of, but not pathognomonic for GAD65 neurological autoimmunity, which has discrete core and secondary manifestations. SPSD was most likely to respond to immunotherapy, while epilepsy was least immunotherapy responsive. Complete immunotherapy response was rare. Serum GAD65 antibody titre >500 nmol/L and cerebellar ataxia predicted poor outcome.